New research supported by the National Institutes of Health?s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) shows that the anticonvulsant medication gabapentin, which is used for certain types of seizures, can be an effective treatment for the pain and other symptoms associated with the common, often hard-to-treat chronic pain disorder, fibromyalgia.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD) announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for doripenem, an investigational carbapenem antibiotic for the treatment of nosocomial pneumonia, a pneumonia that is acquired in a hospital or other healthcare setting.
The G8 leaders promised an increase in investment in programs to fight AIDS, tuberculosis, and malaria, but the $60 billion total will still be only one-third of what the UN says is needed over the next five years. Together, these diseases kill about 16,000 people each day.
In a study that examined the relationship between race, menopausal status and symptoms of obstructive sleep apnea (OSA), middle-aged African-American women were found to be more likely to experience OSA symptoms than their Caucasian counterparts, according to a research abstract that will be presented Monday at SLEEP 2007, the 21st Annual Meeting of the Associated Professional Sleep Societies (APSS).
Students with symptoms of sleep disorders are more likely to receive bad grades in classes such as math, reading and writing than peers without symptoms of sleep disorders, according to a research abstract that will be presented Monday at SLEEP 2007, the 21st Annual Meeting of the Associated Professional Sleep Societies (APSS).
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech AB (OMX NORDIC: ACTI) announced that the companies are initiating a clinical Phase III program for laquinimod, a novel once-daily, orally administered immunomodulatory compound for the treatment of relapsing multiple sclerosis (RMS).
New data demonstrate that pramipexole (Mirapexin?/Sifrol?) is also efficacious and well-tolerated in Restless Legs Syndrome (RLS) patients with daytime RLS symptoms. The data was presented this week at the Movement Disorder Society?s (MDS) 11th International Congress of Parkinson?s Disease and Movement Disorders in Istanbul, Turkey.
GlaxoSmithKline plc announced results from an international, pivotal Phase III study of its investigational non-peptide oral platelet growth factor, Revolade? (eltrombopag). Data from this study showed that eltrombopag at 50-75mg once daily resulted in a statistically significant increase in platelet counts and also reduced bleeding in adult patients with chronic idiopathic thrombocytopenia purpura (ITP).
Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP) announced that the European Commission has approved a new indication for REMICADE(R) (infliximab) allowing for the treatment of severe, active Crohn’s disease (CD) in pediatric patients aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy, or who are intolerant to, or have contraindications for, such therapies.
Male pattern hair loss (MPHL) is a condition that affects as many as 50 percent of men by the age of fifty, but according to a new study, baldness may soon be a treatable condition.